Pharmafile Logo
Pharmafocus logo
Advanced Search

Oncology

Showing 15 posts of 308 posts found.

Research collaboration announced between Oxford University and GSK

January 27, 2025
Research and Development Cancer, Oncology, Oxford University, neoantigens, partnership, research and development

The GSK-Oxford Cancer Immuno-Prevention Programme was announced at the end of January and will focus on researching the prevention of …

News

Combination first-in-line treatment approved for patients with non-small cell lung cancer

January 23, 2025
Research and Development J&J Innovative Medicine, Oncology, approval, non-small cell lung cancer

Johnson & Johnson Innovative Medicine  have announced that the European Commission (EC) has approved a marketing authorisation for the combination …

News

University of Sheffield trial highlights immunotherapy-related improved survival rates for bladder cancer patients

January 14, 2025
Research and Development Endocrinology, Oncology, Sheffield, astranzeneca, bladder cancer, immunotherapy, patients

The University of Sheffield, UK, have announced study results for its trial into the survival rates of patients with operable …

News

NDA in China receives priority review status for lung cancer treatment

January 3, 2025
Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review

HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …

News

Johnson & Johnson receive MHRA approval for BALVERSA

November 8, 2024
Research and Development J&J Innovative Medicine, Oncology, Urology, bladder cancer

BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment …

News

Valneva Scotland supports local cancer charity Team Jak Foundation 

October 31, 2024
Support Services Oncology, Scotland, Valneva Scotland, cancer charity, paediarics, vaccines

Valneva Scotland, the country’s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team Jak, helping towards the organisation’s …

News
Press release

Third application for Orion’s prostate cancer drug submitted by partner Bayer

September 23, 2024
Bayer, Cancer, Oncology, orion, prostate cancer

Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …

News
lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

August 27, 2024
Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …

News

New gastric & gastro-oesophageal junction cancer treatment VYLOY™ ▼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain

August 16, 2024
GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer

Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …

News
Press release

First oral treatment for hormone-sensitive prostate cancer recommended by NICE

August 15, 2024
Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer

Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …

News

China CDE clears Phase 3 Study of Lisafltoclax in Newlly Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome

August 13, 2024
Clinical Research, Research and Development Ascentage Pharma, Oncology

The China Centre for Drug Evaluation (CDE) has cleared the registrational phase 3 study of lisaftoclax in combination with azacitadine …

News
acute_leukemia-all

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy

August 12, 2024
Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells

Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …

News
Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

August 7, 2024
Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …

News
Brain picture

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young adults and adolescents launched by UCLA Health

August 6, 2024
Research and Development Oncology, UCLA Health, adolescent cancer, brain tumour, cancer vaccine, clinical trial

Today, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have announced that they are launching a first-of-its-kind clinical trial to …

News

National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.

August 6, 2024
Research and Development BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease

BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for treatment …

News
Press release
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026